12:00 AM
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TransCon PEG Growth Hormone: Phase II started

Ascendis began a 4-week, double-blind, European Phase II trial to compare 3 doses of once-weekly ACP-001 vs. once-daily growth hormone in 32...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >